Tumors >2 cm in node-negative, HER2-positive breast cancer: comparing neoadjuvant dual-targeted versus adjuvant single-targeted treatment pathways in real-world practice
Therapeutic Advances in Medical Oncology
Published online on July 20, 2026
Abstract
Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Background:The optimal systemic treatment for node-negative, human epidermal growth factor receptor 2 (HER2)-positive breast cancer with tumors >2 cm remains unclear. De-escalation is commonly used for smaller tumors, but evidence supporting the ...
Background:The optimal systemic treatment for node-negative, human epidermal growth factor receptor 2 (HER2)-positive breast cancer with tumors >2 cm remains unclear. De-escalation is commonly used for smaller tumors, but evidence supporting the ...